Market Cap: $5.1B
PI
PTC Therapeutics, Inc.
PTCT
NASDAQ (NASDAQ Global Select)USD
Market Cap: $5.1B
PTC Therapeutics (Ticker: PTCT) aims to strengthen its financial position through a recent private placement of $500 million in Convertible Senior Notes due in 2031. This strategic move is intended to…
PTC Therapeutics Welcomes Jessica Chutter to Its Board of Directors PTC Therapeutics, Inc. recently announces the appointment of Jessica Chutter to its Board of Directors, aiming to bolster its strate…
PTC Therapeutics Strengthens Employee Engagement with New Compensation Package On March 10, 2026, PTC Therapeutics, Inc. announces a significant step in employee engagement and retention as it grants…
PTC Therapeutics Enhances Talent Acquisition through Stock Options and RSUs PTC Therapeutics, Inc. announces a significant step in its human resources strategy with the approval of non-statutory stock…
Navigating Controversy: UniQure's Gene Therapy for Huntington's Disease Under FDA Scrutiny UniQure is embroiled in a dispute with the U.S. Food and Drug Administration (FDA) regarding its gene therapy…
UniQure's Huntington's Disease Therapy Faces FDA Challenges UniQure, a company specializing in gene therapies, currently navigates turbulent waters with the U.S. Food and Drug Administration (FDA) ove…
PTC Therapeutics Confronts Regulatory Challenges in Gene Therapy Development PTC Therapeutics navigates a challenging landscape as regulatory scrutiny becomes a pivotal theme in the gene therapy secto…
Missing source hampers PTC Therapeutics summary request A requested summary for PTC Therapeutics cannot proceed because the user does not supply the underlying article or link. The user message contai…
Missing source delays PTC Therapeutics coverage PTC Therapeutics’ near‑term public narrative is stalled because the requested source material is absent, preventing a targeted summary of company develo…
Headline: Missing Source Material Impedes Same‑Day Coverage of Biotech Name PTC Therapeutics Main Topic — Source Gap Curtails Timely Reporting on Biotech Developments A request for same‑day summaries…
PTC Therapeutics Strengthens Workforce with Strategic RSU Grant PTC Therapeutics, Inc. (NASDAQ: PTCT) announces the approval of 300 restricted stock units (RSUs) for a new non-executive employee, whic…
PTC Therapeutics Expands Workforce with Strategic RSU Grant for New Hire PTC Therapeutics, Inc. announces the approval of 300 restricted stock units (RSUs) for a recently hired non-executive employee,…
PTC Therapeutics Strengthens Workforce with New Hire Inducement Package PTC Therapeutics, Inc. has taken a significant step in enhancing its workforce by approving the issuance of 300 restricted stock…
PTC Therapeutics: Expanding Opportunities in Gene Therapy PTC Therapeutics is making significant strides in the field of gene therapy, building on its expertise in developing innovative treatments for…
PTC Therapeutics Bolsters Workforce with New Employee Equity Incentives PTC Therapeutics, Inc. announces the approval of non-statutory stock options and restricted stock units (RSUs) aimed at attracti…
PTC Therapeutics to Showcase Innovative Approaches at J.P. Morgan Healthcare Conference PTC Therapeutics, Inc., a pioneering biopharmaceutical company, prepares to present at the 44th Annual J.P. Morg…
PTC Therapeutics Prepares to Showcase Innovations at Major Healthcare Conference PTC Therapeutics, Inc., a leading biopharmaceutical company dedicated to developing innovative treatments for rare diso…
PTC Therapeutics Expands Workforce with Strategic Stock Options and RSUs for New Hires PTC Therapeutics, Inc. announces a strategic initiative to enhance its workforce by granting stock options and re…
PTC Therapeutics Expands Workforce with New Employee Inducements PTC Therapeutics, Inc. announces a strategic move to enhance its workforce by approving stock options and restricted stock units (RSUs)…
PTC Therapeutics Expands Workforce with New Stock Options and RSUs for Employees PTC Therapeutics, Inc. announces the approval of stock options and restricted stock units (RSUs) for 15 new employees,…
PTC Therapeutics: Advancements in Genetic Medicine Drive Innovation PTC Therapeutics, a biopharmaceutical company specializing in genetic medicine, is making significant strides in developing therapie…
PTC Therapeutics Advances in Rare Disease Treatments Amid Industry Challenges PTC Therapeutics continues to position itself as a leader in the development of innovative therapies for rare genetic diso…
PTC Therapeutics to Showcase Innovations at Upcoming R&D Day PTC Therapeutics, Inc. announces an upcoming Research and Development (R&D) Day scheduled for December 2, 2025, in New York City. This even…
PTC Therapeutics to Showcase Innovative Developments at Upcoming R&D Day PTC Therapeutics, Inc. is gearing up for an important Research and Development (R&D) Day scheduled for December 2, 2025, at 9:3…
PTC Therapeutics to Showcase Innovations in Rare Disease Treatment at Upcoming R&D Day PTC Therapeutics, Inc. is set to host an R&D Day on December 2, 2025, at 9:30 a.m. EST in New York City, with an…